# NIH Reporter #5R01AI183405-03

Treatment of isoniazid-resistant tuberculosis: closing evidence gaps on safety, effectiveness, and pharmacokinetics of the standard regimen

**Recipient:** SOCIOS EN SALUD SUCURSAL PERU

**Award Amount:** $132,182.00
**Ceiling:** $132,182.00

**Awarded:** July 07, 2026

**Identifier:** 5R01AI183405-03

The study will assess the safety and effectiveness of the 6Lfx-REZ regimen for isoniazid-resistant, rifampicin-sensitive tuberculosis in Peru, and examine levofloxacin and rifampicin drug levels to inform treatment dosing.

### Description

Research to evaluate the safety, tolerability, effectiveness, and pharmacokinetics of the standard regimen for isoniazid-resistant tuberculosis.

[View original record](https://reporter.nih.gov/search/a_XEnEpPR0i-06zXlbqcPw/project-details/11421427)
